All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
On April 25, 2026, the MPN Hub held a live symposium at the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. The symposium was chaired by Jean-Jacques Kiladjian, with presentations from Steffen Koschmieder and Claire Harrison, and included a panel discussion and Q&A with live audience participation. Explore each session below:
At the ESH 2026 MPN Hub symposium, Jean-Jacques Kiladjian reviewed the causes of cytopenias in myelofibrosis, their impact on symptoms, QoL, and outcomes, and the importance of proactive, patient-centered management.
At the ESH 2026 MPN Hub symposium, Steffen Koschmieder discussed therapeutic options for patients with cytopenic myelofibrosis, highlighting the roles of momelotinib, pacritinib, luspatercept, and emerging therapies.
At the ESH 2026 MPN Hub symposium, Claire Harrison discussed the treatment of patients with cytopenic myelofibrosis, reviewing treatment algorithms and providing real‑world insights.
At the European School of Haematology (ESH) 2026 MPN Hub symposium, Jean-Jacques Kiladjian, Steffen Koschmieder, and Claire Harrison discussed future perspectives for the management of cytopenic MF during a panel discussion and Q&A session.
This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Jean-Jacques Kiladjian
Claire Harrison
Steffen Koschmieder